SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively debate the upcoming announcement of the trial's 80th event, with bullish community members highlighting potential acquisition interest from major pharmaceutical companies while bears express skepticism regarding trial integrity and dilution risks. The conversation is heavily focused on the high short interest and the anticipation that positive topline results could trigger a significant market move.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position for imminent Phase 3 clinical data, with many speculating that positive results will drive a material rerating or M&A activity. The community is heavily focused on the potential for the VELA-52 week readout to confirm a best-in-disease profile, while also monitoring strategic updates and potential acquisition interest from major pharmaceutical players.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML remains a central focus for semiconductor investors as it balances robust AI-driven demand and raised FY26 guidance against market scrutiny regarding high-NA EUV adoption timelines and geopolitical export restrictions. The community is actively debating the company's long-term monopolistic moat versus near-term valuation sensitivity, while monitoring heavy institutional flow that continues to rotate into the chip manufacturing infrastructure layer.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing heightened scrutiny and volatility after the FDA placed a clinical hold on its gene therapy programs due to a reported brain tumor, raising significant concerns about the safety and potential genotoxicity of the company's AAV9 platform ahead of a critical PDUFA decision for RGX-121. The community is actively debating whether this hold signals an inevitable complete response letter and potential long-term risks for the broader gene therapy sector, or if the stocks sharp pullback represents an overreaction to programs that represent a smaller portion of the companys pipeline valuation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community speculation as investors closely monitor insider activity, significant institutional ownership, and ongoing patent developments. The conversation is largely driven by anticipation of upcoming clinical trial milestones and potential takeover interest, with the community actively debating the silence from leadership versus the strategic long-term accumulation of shares by management.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is generating intense community discussion due to ongoing speculation surrounding a potential partnership with POSCO and the impact of fluctuating HRC steel prices on the company's valuation. Investors remain deeply divided, with some betting on a short squeeze fueled by significant short interest while others express frustration over management, debt levels, and the stock's sensitivity to broader market manipulation.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to surging interest in the AI infrastructure and 'Neocloud' sector, fueled by its role as an emerging proxy for Cerebras-linked compute capacity and upcoming earnings. The community is actively discussing the stock's thin float, high short interest, and its strategic partnership with Nscale, while speculating on the impact of the upcoming Cerebras IPO.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on the company's strategic role in U.S. critical minerals and nuclear energy, bolstered by federal loan support and its position as the only facility capable of processing both uranium and rare earths at scale. The community remains highly focused on the company's potential to break reliance on China, with discussions emphasizing long-term growth driven by AI data center energy demand and domestic defense supply chain needs.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is experiencing heightened interest as investors shift focus toward potential mergers, acquisitions, and positive clinical trial readouts within the sector. Community sentiment is driven by a mix of optimism over sector rotation, strategic buying during pullbacks, and speculative excitement surrounding individual biotech firms that are gaining regulatory momentum.

United Microelectronics Corp. is engaged in the semiconductor foundry company which provides IC fabrication services, focusing on logic and various technologies to serve all major sectors of the electronics industry. It offers complementary metal-oxide semiconductor logic wafers, mixed signal wafers, radio frequency complementary metal-oxide semiconductor wafers, embedded memory products, high voltage integrated circuits, and complementary metal-oxide semiconductor image sensors. The company was founded on May 22, 1980 and is headquartered in Hsinchu, Taiwan.

United Micro Electronics - ADR

United Microelectronics Corporation

United Microelectronics Corporation is trending as investors digest a series of positive technical breakouts and bullish sentiment regarding the company's long-term competitive positioning within the semiconductor foundry space. The community is actively discussing the firm's strategic focus on specialty technology nodes and the potential for a structural re-rating, with many focusing on its solid balance sheet and role as a key infrastructure provider in the AI-driven data center market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Angi (ANGI) Reports Q1 Loss, Misses Revenue Estimates

Angi (ANGI) delivered earnings and revenue surprises of +46.34% and -1.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Intellinetics, Inc. (INLX) Reports Q3 Loss, Lags Revenue Estimates

Intellinetics (INLX) delivered earnings and revenue surprises of +20.00% and -7.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Gogo (GOGO) Surpasses Q3 Earnings and Revenue Estimates

Gogo (GOGO) delivered earnings and revenue surprises of +42.86% and +0.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

IPG Photonics (IPGP) Surpasses Q3 Earnings and Revenue Estimates

IPG (IPGP) delivered earnings and revenue surprises of +118.75% and +6.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellinetics (INLX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Intellinetics (INLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Intellinetics (INLX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Intellinetics (INLX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Intellinetics, Inc. (INLX) Reports Q2 Loss, Misses Revenue Estimates

Intellinetics (INLX) delivered earnings and revenue surprises of +18.75% and -5.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellinetics, Inc. is a holding company, which engages in the provision of document services and software solutions to private and public sectors. It operates through the Document Management and Document Conversion segments. The Document Management segment allows customers to capture and manage all documents across operations. The Document Conversion segment assists clients as a part of overall document strategy to convert documents from one medium to another, predominantly paper to digital, including migration to software solutions. The company was founded by A. Michael Chretien, Matthew L. Chretien, and Thomas D. Moss on October 3, 1997 and is headquartered in Columbus, OH.

Intellinetics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.87
Prev Close	$6.51
Open	$6.36
Dividend Yield	0.00%
50-Day Moving Average	$6.72
Beta	0.19
Avg. Volume	1,616.71
PE Ratio	-11.03

52-Week High	$14.57
52-Week Low	$5.25
Market Capitalization	$26.39M
EPS (Annual)	-$0.4354
Price to Book	2.51
Revenue Per Employee	$112,812.56

INLXIntellinetics Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest INLX News